Get the Stockscreener App
1.685
3.16%
-0.055
Opko Health Inc stock is traded at $1.685, with a volume of 1.80M.
It is down -3.16% in the last 24 hours and down -3.16% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
See More
Previous Close:
$1.74
Open:
$1.74
24h Volume:
1.80M
Relative Volume:
0.46
Market Cap:
$1.18B
Revenue:
$711.41M
Net Income/Loss:
$-133.73M
P/E Ratio:
-8.8684
EPS:
-0.19
Net Cash Flow:
$-199.99M
1W Performance:
-6.39%
1M Performance:
-3.16%
6M Performance:
+10.86%
1Y Performance:
+40.42%
1-Day Range:
$1.68
$1.745
1-Week Range:
$1.6812
$1.8275
52-Week Range:
$1.15
$2.035
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.685 | 1.18B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
501.06 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
206.07 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
416.42 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.84 | 33.74B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
177.99 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - Yahoo Finance
Charles Schwab Investment Management Inc. Has $5.14 Million Stock Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Zacks Research Weighs in on OPKO Health FY2027 Earnings - MarketBeat
OPKO Health Insider Ups Holding During Year - Simply Wall St
Quote - OPKO Health, Inc.
HC Wainwright Reaffirms "Buy" Rating for OPKO Health (NASDAQ:OPK) - MarketBeat
Best Buy, Las Vegas Sands, Globalstar, Opko Health, Agilent: Stock Moves Unveiled - MSN
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 200,000 Shares - MarketBeat
PRESS RELEASE ISSUED FEBRUARY 4, 2000 - OPKO Health, Inc.
Q2 EPS Estimates for OPKO Health Increased by HC Wainwright - MarketBeat
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock - Yahoo Finance
H.C. Wainwright maintains Buy on Opko Health, $3 target By Investing.com - Investing.com Canada
OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1 - Contract Pharma
Forecasting The Future: 6 Analyst Projections For OPKO Health - Benzinga
Opko and Entera focus on oral care for obesity and metabolic disorders - Yahoo Finance
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld Online
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic - BioSpace
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
Essential Planning LLC. Makes New $506,000 Investment in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
OPKO Health, Entera Bio Collaborate To Develop Oral Dual GLP-1/Glucagon Therapy For Obesity - Nasdaq
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192 Million - Dealbreaker
OPKO and Entera partner to develop obesity pill - Reuters
Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders - MarketWatch
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
OPKO Health (NASDAQ:OPK) Earns Buy Rating from HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Given "Outperform" Rating at Barrington Research - MarketBeat
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192M - MedCity News
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK - MSN
OPKO Health (NASDAQ:OPK) Shares Gap UpStill a Buy? - MarketBeat
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. - Barron's
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? - Insider Monkey
HC Wainwright Reiterates Buy Rating for OPKO Health (NASDAQ:OPK) - Defense World
OPKO Health (NASDAQ:OPK) Earns Outperform Rating from Barrington Research - Defense World
10 Best Stocks Under $3 to Buy Now - Insider Monkey
H.C. Wainwright maintains $3 target on Opko Health stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $3 target on Opko Health stock - Investing.com
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 29 '24 |
Buy |
1.53 |
199,072 |
305,376 |
211,911,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 22 '24 |
Buy |
1.59 |
100,000 |
159,000 |
211,712,405 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 14 '24 |
Buy |
1.62 |
100,000 |
161,980 |
211,612,405 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 08 '24 |
Buy |
1.50 |
280,183 |
421,535 |
211,512,405 |
0.55%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):